DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

Business Wire

2024-11-12

MINNEAPOLIS, November 12, 2024--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s management will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 in New York City, New York. Management will be available for one-on-one meetings throughout the day.

Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241112148074/en/

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2482702406"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2482702406\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2482702406?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Gouep.MkD6EIKbsHOID_vQ--~B/aD0yNTg7dz04MTg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/63ca7240129fe41299608750485d7f49","is_english":true,"pubTime":"2024-11-12 21:23","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2482702406","market":"us","top_or_hot":-1,"title":"DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"258\" src=\"https://s1.yimg.com/uu/api/res/1.2/H6Ad2Cn22RLwbWm4shteXw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/63ca7240129fe41299608750485d7f49\" title=\"\" width=\"818\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>MINNEAPOLIS, November 12, 2024</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/DMAC\">DiaMedica Therapeutics Inc.</a> (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s management will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 in New York City, New York. Management will be available for one-on-one meetings throughout the day.</p>\n<p>Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.</p>\n<p><b><i>About DiaMedica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc.</i></b></p>\n<p>DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20241112148074/en/</span></p>\n<p><b>Contacts</b></p>\n<p>Scott Kellen<br/>Chief Financial Officer<br/>Phone: (763) 496-5118<br/>skellen@diamedica.com<br/><br/><br/></p>\n<p><b>For Investor Inquiries:<br/></b>Mike Moyer<br/>Managing Director, LifeSci Advisors, LLC<br/>mmoyer@lifesciadvisors.com<br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Business Wire</strong><span class=\"h-time small\">2024-11-12 21:23</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body>\n<figure>\n<img border=\"0\" height=\"258\" src=\"https://s1.yimg.com/uu/api/res/1.2/H6Ad2Cn22RLwbWm4shteXw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/63ca7240129fe41299608750485d7f49\" title=\"\" width=\"818\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>MINNEAPOLIS, November 12, 2024</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/DMAC\">DiaMedica Therapeutics Inc.</a> (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s management will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 in New York City, New York. Management will be available for one-on-one meetings throughout the day.</p>\n<p>Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.</p>\n<p><b><i>About DiaMedica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc.</i></b></p>\n<p>DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20241112148074/en/</span></p>\n<p><b>Contacts</b></p>\n<p>Scott Kellen<br/>Chief Financial Officer<br/>Phone: (763) 496-5118<br/>skellen@diamedica.com<br/><br/><br/></p>\n<p><b>For Investor Inquiries:<br/></b>Mike Moyer<br/>Managing Director, LifeSci Advisors, LLC<br/>mmoyer@lifesciadvisors.com<br/><br/></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/diamedica-therapeutics-participate-upcoming-craig-132300254.html\">Business Wire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://finance.yahoo.com/news/diamedica-therapeutics-participate-upcoming-craig-132300254.html","article_id":"2482702406","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Gouep.MkD6EIKbsHOID_vQ--~B/aD0yNTg7dz04MTg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/63ca7240129fe41299608750485d7f49"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482702406","pubTimestamp":1731417780,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"MINNEAPOLIS, November 12, 2024----DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s management will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 in New York City, New York. Management will be available for one-on-one meetings throughout the day.Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant  form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia an","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","DMAC":"DiaMedica Therapeutics Inc.","BK4139":"生物科技","SLCT":"Select Bancorp Inc."},"translate_title":"DiaMedica Therapeutics将参加即将举行的Craig-Hallum第15届年度Alpha Select会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"SLCT":1,"DMAC":0.9},"content_text":"MINNEAPOLIS, November 12, 2024--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s management will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 in New York City, New York. Management will be available for one-on-one meetings throughout the day.\nInvestors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.\nAbout DiaMedica Therapeutics Inc.\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241112148074/en/\nContacts\nScott KellenChief Financial OfficerPhone: (763) 496-5118skellen@diamedica.com\nFor Investor Inquiries:Mike MoyerManaging Director, LifeSci Advisors, LLCmmoyer@lifesciadvisors.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1}}}